Drug
Laromustine clinical trials
Also written Cloretazine and VNP40101M.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2005 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2005 | 3 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Vion Pharmaceuticals (5) · M.D. Anderson Cancer Center (1) · Pediatric Brain Tumor Consortium (1) · Institut Paoli-Calmettes (1) · Viron Therapeutics Inc (1) · Northwestern University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses laromustine is read from its arms, and is right about nine times in ten.
Testing it · 10
- Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional CytarabineTerminatedPhase 1/2Viron Therapeutics IncNCT00655395Written as Laromustine (VNP40101M) and Ara-C
- VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung CancerCompletedPhase 2Vion PharmaceuticalsNCT00282022Written as laromustine
- VNP40101M in Treating Patients With Advanced Solid Tumors or LymphomasCompletedPhase 1Vion PharmaceuticalsNCT00025129Written as laromustine
- VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromeCompletedPhase 1Vion PharmaceuticalsNCT00049686Written as laromustine
- VNP40101M in Treating Patients With Advanced or Metastatic CancerCompletedPhase 1Vion PharmaceuticalsNCT00049699Written as laromustine
- VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative DisordersCompletedPhase 1/2Vion PharmaceuticalsNCT00304005Written as laromustine
- Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT00521859Written as Cloretazine
- VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant GliomaTerminatedPhase 1Northwestern UniversityNCT00516282Written as CLORETAZINE
- VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsCompletedPhase 1Pediatric Brain Tumor ConsortiumNCT00098761Written as laromustine
- Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedPhase 1/2Institut Paoli-CalmettesNCT00840684Written as laromustine
Given in every arm · 1 — laromustine is usual care beside what is tested
Codes
What other systems call laromustine · ClinicalTrials.gg INT004624
- MeSH (NLM) C483604laromustineOne source NLM
- UNII (FDA) 14J2G0U3NQLAROMUSTINEConfirmed FDA, NLM, Wikidata
- Wikidata Q26841309laromustineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2653LaromustineOne source FDA
- DrugBank DB05817One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C483604 | laromustine | One source NLM |
| UNII (FDA) | 14J2G0U3NQ | LAROMUSTINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q26841309 | laromustine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2653 | Laromustine | One source FDA |
| DrugBank | DB05817 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.